Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
Authors: Gonzalez-Lugo Jesus D , Kambhampati Suman , Yacoub Abdulraheem , Donnellan William , Bhagat Prafulla , Fehn Karen , Remy Cassady , Jasra Sakshi , Kazemi Mohammad , Mantzaris Ioannis , Sica R. Alejandro , Bachier-Rodriguez Lizamarie , Goldfinger Mendel , Kornblum Noah , Gritsman Kira , Braunschweig Ira , Steidl Ulrich G. , Will Britta , Shastri Aditi , Verma Amit 
Published: November 2021

Introduction:

Lenalidomide (LEN) is approved for treatment of Myelodysplastic Syndrome (MDS) with chromosome 5q deletion (del 5q) as it has shown to induce disease remission and transfusion independence in close to 65% of this population. For patients (pts) without del 5q, LEN has shown to reduce transfusion needs in one-quarter of pts, but its use is limited by significant thrombocytopenia, and pts with platelet counts (PLTs) &lt;50,000 have been excluded from these trials. Eltrombopag (ELT), a TPO-R agonist, has proven to be effective increasing PLTs in MDS. Furthermore, preclinical data has demonstrated that ELT can reverse anti-megakaryopoietic effects of LEN in MDS patient samples. Based on this rationale, we conducted a study to determine the safety and efficacy of the combination of eltrombopag and lenalidomide (ELT/LEN) in low and intermediate (low/int) risk MDS (NCT01772420).

Methods:

Pts aged ≥18 years with low/int risk MDS per IPSS, or non-proliferative chronic myelomonocytic leukemia (CMML), with bone marrow blasts &lt;10% at baseline, without prior exposure to LEN or ELT and with symptomatic anemia were enrolled. Pts with PLTs ≥50,000 (Arm A) received LEN alone at 10mg PO daily (qd) on days 1-21. If PLTs fell &lt;50,000, LEN was discontinued and ELT PO qd given until PLTs ≥50,000 for 2 weeks (wks). Pts then resumed LEN. If PLTs fell &lt;50,000 again, pts received ELT as before and then received concomitant LEN and ELT. Pts with PLTs &lt;50,000 (Arm B) received ELT alone qd on days 1-28 until PLTs ≥50,000 for 2 wks. Pts then received treatment as in arm A. Both arms had 28-day cycles. ELT was initiated at 100mg PO qd and escalated up to 300mg PO qd until response was achieved. The primary objectives of the study were to evaluate the rate of hematologic improvement (HI) of ELT/LEN as per 2006 IWG criteria, and to evaluate the safety and tolerability of the combination.

Results:

51 pts were accrued, with 44 evaluable pts. Of evaluable pts, most were male (70%), median age was 71 years (range 34-93). 42 (95%) pts had MDS and 2 (5%) CMML. 24 (55%) pts were low-risk per IPSS-R score. 28 (64%) pts were treatment-naïve and 16 (36%) had received ≥1lines of treatment, including erythropoiesis stimulating agents. 24 (55%) pts were assigned to arm A and 20 (45%) pts to arm B.

ELT/LEN was well tolerated. Non-hematological grade 3-4 treatment-related adverse events were few, including G3 hyperbilirubinemia (7%), G3 transaminitis (2%), G3 diarrhea (2%), G3 arthralgias (2%). 2 pts had major bleeding events; there were 2 deaths, one attributable to pneumonia and one to gallbladder cancer. 1 of 31 pts who received ELT had a reversible increase in peripheral blasts while on treatment, and 1 pt had development of marrow fibrosis after 6 years of ELT.

ITT analysis of total population (51) revealed an objective response (ORR) of 35%; ORR of 32% (9/28) in arm A (PLTs ≥50,000),and 39% (9/23) in arm B (PLTs &lt;50,000).Of the 44 evaluable pts, ORR was 40.9% (18/44); 37.5% (9/24) in arm A and 45% (9/20) in arm B. 13 (30%) pts achieved RBC transfusion-independence (RBC-TI), 11 (25%) pts had platelet HI, 6 (14%) pts had bilineage responses, and 3 (7%) achieved complete remission (CR).

17 pts received ELT alone, among these ORR was 41% (7/17), with 29% achieving bilineage responses, 1 CR. 13 pts received LEN alone, ORR was 46% (6/13), of these 100% achieved RBC-TI. 14 pts received ELT/LEN combination, ORR was 36%, 2 (14%) achieved bilineage responses and 2 (14%) CR. There were 2 HIV-positive MDS pts, both achieved sustained CRs, one with ELT alone and one with ELT/LEN combination.

Mean time to response was 9.4 wks (range 6-12.4) for ELT alone, 10.9 wks (range 2.4-16) for LEN alone, and 9.9 wks (range 2-20) for ELT/LEN combination. Mean duration of response was 102 wks for ELT (range 8-ongoing), 63 wks (range 25-ongoing) for LEN, and 66 wks (range 8.3-ongoing) for ELT/LEN as of last follow-up.

Conclusions:

Treatment with ELT/LEN demonstrates good efficacy with ORR of 40.9%, response durability and an acceptable safety profile for evaluable pts with low/int risk MDS. ELT can lead to single agent responses with an acceptable safety profile and sizable proportion of multilineage responses. One patient developed bone marrow fibrosis and one patient had a transient increase in blasts, hence, undermining these pre-existing safety concerns. Lastly, using our study schema 32% of pts were able to initiate or continue LEN achieving a 36% ORR whereas in prior studies these pts would have been excluded.

Figure 1 Figure 1.

Disclosures

Yacoub: Agios: Membership on an entity's Board of Directors or advisory committees; Acceleron Pharma: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Incyte: Speakers Bureau. Gritsman: iOnctura: Research Funding. Shastri: Kymera Therapeutics: Research Funding; Onclive: Honoraria; GLC: Consultancy; Guidepoint: Consultancy. Verma: Celgene: Consultancy; Acceleron: Consultancy; Novartis: Consultancy; Stelexis: Consultancy, Current equity holder in publicly-traded company; Eli Lilly: Research Funding; Curis: Research Funding; Medpacto: Research Funding; Incyte: Research Funding; Stelexis: Current equity holder in publicly-traded company; Throws Exception: Current equity holder in publicly-traded company; GSK: Research Funding; BMS: Research Funding.

OffLabel Disclosure:

Lenalidomide has shown to be effective achieving RBC Transfusion Independence in Myelodysplastic Syndromes without deletion 5q Eltrombopag is a TPO-R agonist, its purpose in this trial is to evaluate if it would increase platelet counts in patients with Myelodisplastic Syndrome.